S6.1.1-12. Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban com- pared to heparin/vitamin K antagonist in patients with atrial fibril- lation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39:2959 71. S6.1.1-13. Airaksinen KEJ, Gr nberg T, Nuotio I, et al. Thromboembolic com- plications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62:1187 92. S6.1.1-14. Garg A, Khunger M, Seicean S, et al. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. J Am Coll Cardiol EP. 2016;2:487 94. S6.1.1-15. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echo- cardiography to guide cardioversion in patients with atrial fibrilla- tion. N Engl J Med. 2001;344:1411 20. S6.1.1-16. von Besser K, Mills AM. Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation? Ann Emerg Med. 2011;58:517 20. S6.1.1-17. Pfizer. Study of the blood thinner, apixaban, for patients who have an abnormal heart rhythm (atrial fibrillation) and expected to have treatment to put them back into a normal heart rhythm (cardio- version) (EMANATE). Available at: https://www.clinicaltrials.gov. Identifier: NCT02100228. Accessed November 22, 2017. S6.1.1-18. Nuotio I, Hartikainen JEK, Gr nberg T, et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312:647 9. S6.1.1-19. Bah A, Nuotio I, Gronberg T, et al. Sex, age, and time to cardiover- sion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study. Ann Med. 2017;49:254 9. S6.1.1-20. Kleemann T, Becker T, Strauss M, et al. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22:1403 8. 6.3.4. 